In this interview, Noel Bairey Merz, MD, FACC, and Alison L. Bailey, MD, FACC discuss the top takeaways from 2023 in Preventive Cardiology including the CLEAR-Outcomes, REPRIEVE, and SELECT trials.

Related References:

1. Lincoff, A. M., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine. https://doi.org/10.1056/nejmoa2307563
2. Nissen, S. E., Lincoff, A. M., Brennan, D. M., Ray, K. K., Mason, D., Kastelein, J. J., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., Bays, H., Moriarty, P. M., Menon, V., Grobbee, D. E., Louie, M. J., Chen, C., Li, N., Bloedon, L. T., Robinson, P., . . . Nicholls, S. J. (2023). Bempedoic acid and cardiovascular outcomes in Statin-Intolerant patients. The New England Journal of Medicine, 388(15), 1353–1364. https://doi.org/10.1056/nejmoa2215024
3. Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Wright, R. S., Vikarunnessa, S., Talloczy, Z., Zhang, X., Maheux, P., Lesogor, A., & Landmesser, U. (2023). Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. The Lancet Diabetes & Endocrinology, 11(2), 109–119. https://doi.org/10.1016/s2213-8587(22)00353-9
4. Khan, S. S., Coresh, J., Pencina, M. J., Ndumele, C. E., Rangaswami, J., Chow, S. L., Palaniappan, L., Sperling, L. S., Virani, S. S., Ho, J. E., Neeland, I. J., Tuttle, K. R., Singh, R. R., Elkind, M. S., & Lloyd‐Jones, D. M. (2023). Novel Prediction Equations for Absolute Risk Assessment of total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A scientific Statement from the American Heart Association. Circulation. https://doi.org/10.1161/cir.0000000000001191